Validation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival

Baysal M., Sadri S., Gül Ö. Ö., Köse E., Baysal S., GÜRSOY V.

Journal of Hematopathology, cilt.18, sa.1, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1007/s12308-025-00668-0
  • Dergi Adı: Journal of Hematopathology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: Essential thrombocythemia, Myeloproliferative neoplasms, Polycythemia vera, Triple A
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: The Triple A model has recently been developed and validated in essential thrombocythemia (ET) and polycythemia vera (PV). However, external validation in diverse populations remains unclear. Purpose: The purpose of this study was to externally validate the Triple A prognostic model in a Turkish cohort of patients with ET and PV. Methods: A retrospective analysis was conducted at two centers in Bursa, Türkiye, involving patients diagnosed with ET or PV under the World Health Organization (WHO) 2016/2022 criteria between 2014 and 2024. Results: While the Triple A model has significantly separated the ET patients with a median follow-up of 47 months (p = 0.015), no significant difference was observed in PV patients in terms of survival (p = 0.87). For thrombosis-free survival (TFS), Fine and Gray’s competing risk analysis showed a significant separation with the Triple A model in ET (p = 0.017). Conclusion: While the Triple A model was validated as a practical prognostic tool in ET, it demonstrated limited utility in PV. Further multicenter studies are needed to refine risk stratification in PV.